Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study — preliminary results

Obońska, Karolina; Kasprzak, Michał; Tymosiak, Kamila; Fabiszak, Tomasz; Krintus, Magdalena; Kubica, Jacek

doi:10.5603/cj.a2020.0166

Cited by 4 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Схожие данные получены в исследованиях других авторов. Так, польские исследователи провели РКИ ROSEZE (Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration) по оценке эффективности фиксированной комбинации розувастатин / эзетимиб (10/10 мг) и оценке связи со временем приема препарата [33]. В исследование включены 83 пациента с ИБС и ДЛП, у которых на монотерапии статинами в течение 6 нед.…”

Section: фиксированные комбинации препаратовunclassified

“…Было показано, что комбинация розувастатин / эзетимиб в фиксированных дозах значимо и длительно снижает уровень ХС ЛНП, независимо от времени приема препарата, при этом терапия была безопасной и хорошо переносилась. Авторы исследования рекомендовали назначение фиксированной комбинации розувастатин / эзетимиб утром с большей частью других препаратов, т. к. эта модификация улучшала приверженность к ГЛТ по сравнению с традиционным приемом статинов вечером [33].…”

Section: фиксированные комбинации препаратовunclassified

See 1 more Smart Citation

Combined hypolipidemic therapy with rosuvastatin and ezetimibe is the key to success in the treatment and prevention of cardiovascular diseases

Kolmakova,

Alekseeva,

Tmoyan

et al. 2024

Medicinskij sovet

View full text Add to dashboard Cite

The treatment of atherosclerotic cardiovascular diseases (ASCVD) is actual worldwide and in Russia as the main reason of morbidity, mortality, invalidation of the working population and national economic damage. The main reasons of developing and progressing of CVD are hypercholesterolemia and dyslipidemia (DLP). DLP, as the main factor of the occurrence and progression of atherosclerosis, represent the most relevant modifiable factor of ASCVD. According to the epidemiological study of ESSE-RF, every second adult in Russia has DLP, every fifth – elevated total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels, which makes the problem of complex individual lipid-lowering therapy actual. A proportional reduction of risk of ASCVD depends on the absolute reduction in blood levels of LDL-C. Statins remain the main group of drugs that significantly reduce LDL-C level. Rosuvastatin, which has the peak inhibitory activity against HMG-CoA reductase, used in daily doses of 10–40 mg, exhibits high lipid-lowering efficiency already at the initial daily dose, increasing with the rising dose. The combination of a statin with ezetimibe is recommended to achieve target LDL-C level, allows to reduce the dose of statin while maintaining excellent LDL-C lowering efficiency with good safety profile. Fixed combination of statin/ezetimibe in patients at very high ASCVD risk has been shown to be more effective than the same free combination, and reducing of taken pills increases adherence to treatment. The fixed combination of rosuvastatin/ezetimibe, presented on the Russian pharmacological market with Rosulip Plus, can be considered as the drug of choice in patients with DLP of high and very high cardiovascular risk, both from clinical and economic point of view.

show abstract

Section: фиксированные комбинации препаратовunclassified

Combined hypolipidemic therapy with rosuvastatin and ezetimibe is the key to success in the treatment and prevention of cardiovascular diseases

Kolmakova,

Alekseeva,

Tmoyan

et al. 2024

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

“…Currently, there is no approved Lp(a)-lowering treatment [13]. Controversial results have been reported regarding the effect of hypolipidemic treatment on Lp(a) levels [14][15][16][17][18]. Statins and fibrates tend to increase Lp(a) levels [14,18], omega-3 fatty acids have a neutral effect [19], ezetimibe seems to have a beneficial effect [20], while niacin, although it lowers Lp(a) levels [21], is not available on the European market.…”

Section: Introductionmentioning

confidence: 99%

The effect of rosuvastatin alone or in combination with fenofibrate or omega-3 fatty acids on lipoprotein(a) levels in patients with mixed hyperlipidemia

Agouridis,

Filippatos,

Kostapanos

et al. 2024

Arch Med Sci Atheroscler Dis

View full text Add to dashboard Cite

IntroductionLipoprotein(a) [Lp(a)] is a strong, genetically determined, pathogenetic factor of atherosclerotic cardiovascular disease (ASCVD). The aim of this post-hoc analysis was to compare the effect of hypolipidemic treatment on Lp(a) levels of patients with mixed hyperlipidemia.Material and methodsWe previously randomized patients with mixed hyperlipidemia (low-density lipoprotein [LDL-C] > 160 mg/dl and triglycerides > 200 mg/dl) to rosuvastatin monotherapy 40 mg/day (R group, n = 30) or rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day (RF group, n = 30) or omega-3 fatty acids 2 g/day (RΩ group, n = 30). In the present post-hoc analysis, we included only the patients whose Lp(a) levels were assessed (16, 16 and 15 in the R, RF and RΩ groups, respectively). Lipid profile and Lp(a) were measured at baseline and after 3 months of treatment.ResultsSignificant reductions in total cholesterol, LDL-C, non-high-density lipoprotein-cholesterol (non-HDL-C) and triglyceride levels were observed in all groups. A significant increase in Lp(a) levels was noted in the R (p = 0.017) and RF (p = 0.029) groups, while no significant difference was seen in the RΩ group (p = NS). Regarding Lp(a) elevations, no differences were found between groups. In the R group, a strong negative correlation between the changes in Lp(a) and LDL-C (r = –0.500, p = 0.049) was observed, while a significant negative correlation between the changes in Lp(a) and triglycerides (r = –0.531, p = 0.034) was noted in the RF group.ConclusionsRosuvastatin and/or fenofibrate treatment increases Lp(a) levels in patients with mixed hyperlipidemia. Novel therapies should target Lp(a) level reduction to decrease the residual ASCVD risk in patients with mixed hyperlipidemia.

show abstract

“…However, a considerable number of patients on statins do not achieve target LDLC levels, even at maximally tolerated statin doses, or are intolerant to intensive statin therapy. The ROSEZE study showed that treatment with rosuvastatin and ezetimibe in patients with coronary artery disease previously ineffectively treated with statin only, further reduced LDL-C levels by an average of almost 40% and by as much as 60% in those whose baseline LDL-C level was in the highest quartile [5,6]. This effect was accompanied by a significant reduction of triglycerides (TG) by 15% and of hs-CRP by 23% after switching from monotherapy with a statin to double hypolipemic treatment (DHT) with rosuvastatin and ezetimibe.…”

mentioning

confidence: 99%

“…This effect was accompanied by a significant reduction of triglycerides (TG) by 15% and of hs-CRP by 23% after switching from monotherapy with a statin to double hypolipemic treatment (DHT) with rosuvastatin and ezetimibe. Despite this impressive LDL-C reduction 27% of patients still did not achieve desired therapeutic target [6]. Hypolipemic and antiinflammatory effects of a diet based on a high intake of omega3 fatty acids and balanced omega6/omega3 ratio in patients at high cardiovascular risk should also be taken into account as a possible supplementary option [7].…”

mentioning

confidence: 99%

From cardiovascular prevention to treatment of critically ill COVID-19 patients

Kubica

2022

Medical Research Journal

View full text Add to dashboard Cite

From cardiovascular prevention to treatment of critically ill COVID-19 patientsThis article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

show abstract

Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study — preliminary results

Cited by 4 publications

References 40 publications

Combined hypolipidemic therapy with rosuvastatin and ezetimibe is the key to success in the treatment and prevention of cardiovascular diseases

Combined hypolipidemic therapy with rosuvastatin and ezetimibe is the key to success in the treatment and prevention of cardiovascular diseases

The effect of rosuvastatin alone or in combination with fenofibrate or omega-3 fatty acids on lipoprotein(a) levels in patients with mixed hyperlipidemia

From cardiovascular prevention to treatment of critically ill COVID-19 patients

Contact Info

Product

Resources

About